Title : The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE-/-FXR-/- Mice.

Pub. Date : 2021 Dec

PMID : 34986301






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Treatment with a PPARalpha agonist, but not with a PPARgamma agonist, partly reversed atherosclerosis and hepatic steatosis, and decreased plasma triglyceride levels in the ApoE-/-FXR-/- mice, in association with increased mRNA expression of CD36 and FATP and decreased expression of ApoC2 and ApoC3 (liver). Triglycerides peroxisome proliferator activated receptor alpha Mus musculus
2 CONCLUSION: Loss of FXR is associated with aggravation of atherosclerosis and hepatic steatosis in ApoE-deficient mice, which could be reversed by a PPARalpha agonist through induction of fatty acid uptake, beta-oxidation, and triglyceride hydrolysis. Triglycerides peroxisome proliferator activated receptor alpha Mus musculus